JPMorgan Chase & Co. set a GBX 5,500 ($77.12) target price on AstraZeneca (LON:AZN) in a research report sent to investors on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the topic of a number of other reports. UBS Group reissued a neutral rating on shares of AstraZeneca in a report on Monday, January 15th. Jefferies Group reissued a hold rating and set a GBX 5,100 ($71.51) target price on shares of AstraZeneca in a report on Thursday, November 16th. Deutsche Bank reissued a buy rating and set a GBX 5,600 ($78.52) target price on shares of AstraZeneca in a report on Wednesday, November 1st. Kepler Capital Markets boosted their target price on shares of AstraZeneca from GBX 5,250 ($73.61) to GBX 5,300 ($74.31) and gave the stock a buy rating in a report on Tuesday, February 6th. Finally, Morgan Stanley set a GBX 5,000 ($70.11) target price on shares of AstraZeneca and gave the stock a neutral rating in a report on Friday, November 10th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of GBX 5,211.65 ($73.07).

Shares of AstraZeneca (LON AZN) opened at GBX 4,770 ($66.88) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($59.73) and a 1-year high of GBX 5,520 ($77.40). The firm has a market cap of $60,400.00 and a P/E ratio of 2,805.88.

The firm also recently disclosed a dividend, which will be paid on Monday, March 19th. Shareholders of record on Thursday, February 15th will be issued a dividend of GBX 133.60 ($1.87) per share. This is an increase from AstraZeneca’s previous dividend of $68.90. The ex-dividend date is Thursday, February 15th. This represents a yield of 2.8%.

In other AstraZeneca news, insider Philip A. J. Broadley acquired 415 shares of the stock in a transaction on Friday, February 2nd. The shares were purchased at an average price of GBX 4,846 ($67.95) per share, for a total transaction of £20,110.90 ($28,198.12).

TRADEMARK VIOLATION WARNING: “AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. Analysts” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://theolympiareport.com/2018/02/12/astrazeneca-azn-given-a-gbx-5500-price-target-by-jpmorgan-chase-co-analysts.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.